Revenue
No reported data
Climb Bio, Inc. (CLYM)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $46.7M | $14.3M | $15.4M | $26.2M | $23.3M | $8.8M |
| Operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M | $20.9M |
| Operating income | −$67.9M | −$82.0M | −$40.3M | −$45.1M | −$35.7M | −$20.9M |
| EBITDAderived | −$67.8M | −$82.0M | — | — | — | — |
| Net income | −$59.9M | −$73.9M | −$35.1M | −$45.2M | −$47.5M | −$20.7M |
| Basic EPSper diluted share | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | -$10.49 |
| Diluted EPSper diluted share | -$0.88 | -$1.53 | -$1.30 | -$1.72 | -$4.24 | -$10.49 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Brennan AoifePresident and CEO | SellCommon Stock | 30.9K | $13.17 | $407.0K | 87.7K |
| Feb 26, 2026Form 4 · 10b5-1 | Thomas Stephen BasilDirector | SellCommon Stock | 16.3K | $7.01 | $114.4K | 154.7K |
| Feb 25, 2026Form 4 · 10b5-1 | Thomas Stephen BasilDirector | SellCommon Stock | 33.7K | $7.00 | $235.8K | 171.0K |
| Feb 13, 2026Form 4 · 10b5-1 | Thomas Stephen BasilDirector | SellCommon Stock | 10.0K | $5.81 | $58.1K | 204.7K |
| Feb 12, 2026Form 4 · 10b5-1 | Thomas Stephen BasilDirector | SellCommon Stock | 90.0K | $5.23 | $470.7K | 214.7K |